摘要
目的探讨扶正化瘀胶囊联合恩替卡韦治疗乙肝肝硬化的临床效果。方法选取2013年1月~2016年12月宿迁市钟吾医院住院治疗的乙肝肝硬化120例随机分为观察组60例、对照组60例。两组患者均给予复方甘草酸苷、还原型谷胱甘肽、保肝降酶治疗,对照组口服恩替卡韦分散片,0.5 mg/次,每日1次。观察组在对照组治疗基础上给予扶正化瘀胶囊口服,每次0.2 g,每日3次。观察两组治疗前及治疗后6个月的丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、白蛋白(Alb)、总胆红素(TBil)、Child-Pugh评分、HBV-DNA定量、层粘连蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、透明质酸(HA),门静脉主干平均血流速度(v)、门静脉主干内径(D)。结果治疗后,两组的ALT、AST、Alb、TBil、LN、Ⅳ-C、HA、Child-Pugh评分、HBV-DNA定量明显好于治疗前(P<0.05)。观察组治疗后的Alb、Child-Pugh评分、LN、Ⅳ-C、HA明显好于对照组(P<0.05)。对照组治疗后的门静脉主干平均血流速度(v)、门静脉主干内径(D)虽然较治疗前有改善但差异均无统计学意义(P>0.05)。观察组治疗后的门静脉主干平均血流速度(v)好于治疗前(P<0.05),门静脉主干内径(D)虽然较治疗前有改善但差异无统计学意义(P>0.05)。结论恩替卡韦治疗乙肝肝硬化时可迅速抑制病毒复制,降低外周血液乙肝病毒数量,使肝功能恢复正常,联合扶正化瘀胶囊时可降低Child-Pugh评分,提高Alb水平,改善肝纤维化指标,改善门静脉血流动力。
Objective To investigate the clinical effect of Fuzheng Huayu Capsules combined with Entecavir in the treatment of liver cirrhosis of hepatitis B.Methods From January 2013 to December 2016,120 patients with liver cirrhosis of hepatitis B treated in Zhongwu Hospital of Suqian City were selected and they were divided into the observation group （n=60） and control group （n=60） in random.The Compound Glycyrrhizin,Reduced Glutathione,liver protection, and enzyme decrease were provided in both groups.In the control group,oral administration of Entecavir Dispersible Tablets was applied,0.5 mg each time,once a day.In the observation group,Fuzheng Huayu Capsules for oral administra- tion was adopted,0.2 g each time,3 times per day.Alanine transaminase （ALT）,aspartate aminotransferase （AST）,albumin （Alb）,total bilirubin （TBil）,Child-Pugh score,HBV-DNA quantitative,laminin （LN）, 1V-collagen （IV-C）,hyaluronic acid （HA）,mean flow velocity of main portal vein （v）,and internal diameter of portal vein （D） were compared and observed in the two groups before and after 6 months treatment.Results After treatment,ALT,AST,Alb,TBil,LN,IV-C,HA,Child-Push score,and HBV-DNA quantitative were significantly better than those before treatment （P〈0.OS）.Alb,Child-Pugh score, LN,1V-C,and HA in the observation group were all better than those in the control group after therapy （P〈0.05）.There was no great difference in improvement of mean flow velocity of main portal vein （v）,and internal diameter of portal vein （D） in the control group compared with that before （P〉0.05）.In the observation group,the improvement of mean flow velocity of main portal vein （v） was better than that before with a statistical difference.Meanwhile,internal diameter of portal vein （D） in the observation group after therapy was greatly improved but without statistical significance （P〉0.05）.Conclusion Entecavir treating liver cirrhosis of hepatitis B can swiftly inhibit viral replication and
出处
《中国当代医药》
2017年第35期147-149,152,共4页
China Modern Medicine
关键词
乙肝肝硬化
扶正化瘀胶囊
恩替卡韦
乙肝病毒
肝功能
门静脉
白蛋白
Liver cirrhosis of hepatitis B
Fuzheng Huayu Capsules
Entecavir
Hepatitis B virus
Liver function
Portal vein
Albumin
